Recent Updates
Recently added Catalysts
SEER Positive Sentiment Score: 65/100

Seer to Report First Quarter 2023 Financial Results on May 9, 2023

Key Takeaway: Seer, Inc. (Nasdaq: SEER) will announce its financial results for the first quarter of 2023 after market close on May 9, 2023. The company is known for its innovative Proteograph Product Suite aimed at enhancing proteomic analysis. A conference call will be held at 1:30 p.m. Pacific Time to discuss these results, which can be accessed live through Seer's website. The Proteograph technology is not intended for diagnostic use, underlining its focus on research applications.

Market Sentiment Analysis

POSITIVE FACTORS

  • Seer is set to report financial results, indicating ongoing business operations.
  • The Proteograph Product Suite offers advanced capabilities for proteomic analysis.
  • Seer's technology is designed to be user-friendly and suitable for various labs.

Full Press Release Details

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Frequently Asked Questions

When will Seer, Inc. report its Q1 2023 financial results?

Seer, Inc. will report its Q1 2023 financial results on May 9, 2023.

What is Seer's Proteograph Product Suite?

The Proteograph Product Suite offers an integrated solution for advanced proteomic analysis.

Where can I watch Seer's upcoming conference call?

The conference call will be webcast live on Seer’s investor website.

Is Seer's Proteograph Product Suite for diagnostic use?

No, the Proteograph Product Suite is for research use only.

What technology does Seer's platform utilize?

Seer's platform uses engineered nanoparticles for deep proteomic analysis.

Last updated: Apr 20, 2023